FDA Documentation (updated)

FDA Downgraded Zorbium® Oversight

The Alarming Discovery

Documents obtained through a Freedom of Information Act (FOIA) request reveal that the FDA reduced oversight of Zorbium® precisely when adverse event reports were escalating. This counterintuitive regulatory decision raises serious questions about drug safety monitoring.

What the FDA Documents Show

Timeline of Events

January 2022 – February 2024:

  • 1,933 total adverse event reports received
  • 1,828 reports specifically for cats (approved species)
  • 1,052 NEW cat reports during this review period alone
  • 38 human exposure reports (mostly veterinary staff exposure)
  • 7 dog reports (despite approval only for cats)

FDA’s Response: Downgrade, Not Action

Despite these escalating numbers, the FDA:

  • ✗ Moved Zorbium® to “non-Tier 1 status” (reduced monitoring)
  • ✗ Determined “no additional actions needed”
  • ✗ Recommended only to “continue monitoring”
  • ✗ Did not require label changes, warnings, or restrictions

The Critical Contradiction

Manufacturer’s Own Admission

Elanco, the manufacturer, stated in the FDA documents:

“Equilibrium of distribution has not been achieved at this point in the lifecycle of this product. The estimated number of felines treated based on product distribution is likely overestimated.”

What this means:

  • The manufacturer cannot accurately calculate how many cats have actually received Zorbium®
  • If fewer cats were treated than estimated, the adverse event rate would be HIGHER than reported
  • Without accurate exposure data, true risk assessment is impossible

The Math Problem

If exposure is overestimated, then:

  • Reported adverse events ÷ Actual treated animals = Higher risk rate
  • Example: 1,828 reports ÷ 10,000 cats = 18.3% rate
  • But if only 8,000 cats were treated: 1,828 ÷ 8,000 = 22.9% rate

The FDA accepted a benefit-risk analysis based on numbers the manufacturer admits are inaccurate.

Most Common Serious Adverse Events

From the FDA’s own review documents:

Top Clinical Signs Reported:

  1. Behavioral disorder: 504 reports (26% frequency)
  2. Impaired consciousness
  3. Bradycardia (dangerously slow heart rate)
  4. Loss of consciousness
  5. Musculoskeletal disorders

These are not minor side effects – these are serious, life-threatening conditions.

The 18-Month Information Gap

Critical delay in transparency:

  • Latest FDA review completed: March 28, 2024
  • Documents released to public: September 24, 2025
  • Information delay: 18 months

Impact: Veterinarians and cat owners made treatment decisions for 18 months without knowing the FDA had documented:

  • 1,052 new adverse events in cats
  • 38 human exposure incidents
  • Off-label use in inappropriate species
  • Manufacturer’s admission of inaccurate exposure data

Off-Label Use Red Flags

Despite FDA approval only for cats, only for post-operative pain:

Documented misuse:

  • Dogs received Zorbium®
  • Alternative routes of administration (IV, subcutaneous, oral) instead of approved topical-only
  • Use for non-surgical conditions
  • Use in exotic species (documented elsewhere: horse, bird, mice)

The FDA identified this misuse but took no action to restrict prescribing or enhance veterinary education.

Regulatory Capture Concerns

Standard Process vs. What Happened

When adverse events escalate, regulators typically:

  • ✓ Increase monitoring (move to Tier 1 status)
  • ✓ Require label updates with black box warnings
  • ✓ Mandate risk communication to veterinarians
  • ✓ Investigate causality of deaths
  • ✓ Compare safety to alternative medications

What the FDA actually did:

  • ✗ Decreased monitoring (moved to non-Tier 1)
  • ✗ Accepted manufacturer’s benefit-risk conclusion without independent analysis
  • ✗ Reviewed deaths “regardless of causality” and found “no verified signals”
  • ✗ No comparative safety analysis
  • ✗ No enhanced warnings or restrictions

What Was Redacted

Extensive portions of the documents were withheld under trade secret protections:

Hidden from public view:

  • Actual number of tubes distributed
  • Precise number of cats treated (exposure data)
  • Specific adverse event counts in multiple sections
  • Manufacturing and quality control information
  • Batch/lot analysis linking deaths to specific product

Without this data, independent safety analysis is impossible.

Current Status and Ongoing Concerns

As of October 2025:

  • Cumulative adverse event reports now exceed 2,800
  • Confirmed deaths: 301 (per latest FOIA response)
  • Community-reported data shows 41.3% mortality rate in 104 cases
  • Off-label use continues
  • FDA has taken no additional regulatory action

The pattern continues:

  • Adverse events escalate
  • FDA reviews and finds “no action needed”
  • Public receives information 18 months late
  • Cats continue to die

Take Action

If your cat experienced adverse reactions to Zorbium®:

  1. Report to FDA: FDA Adverse Event Reporting Portal
  2. Report to us: Share your experience on ZorbiumLawsuit.com
  3. Warn others: Talk to your veterinarian about safer alternatives
  4. Demand transparency: Contact your elected representatives about FDA oversight

The FDA’s own documents prove they knew about serious safety concerns and chose to reduce oversight rather than protect cats.

Documents obtained via FOIA Request #2025-3031. FDA reviews dated through March 28, 2024. Public release: September 24, 2025.

What the Clinical Studies Documented

The original FDA approval documents and Elanco’s marketing materials both acknowledge certain behavioral effects of Zorbium®:

  • Euphoria: Described in the clinical studies as “exaggerated social and playful behavior with meowing, rolling, kneading with forepaws, play-biting, or rubbing”
  • Dysphoria: Recorded as “a state of anxiety or agitation with staring, hyper-responsiveness, sudden movements, vocalization, fearful or aggressive behaviors”
  • Mydriasis: Dilated pupils observed in most cats given Zorbium®, lasting up to 48 hours after administration

According to the FDA approval document, these effects were “dose independent,” meaning they occurred across all dosage groups and weren’t limited to higher doses.

Connection to Current FDA Adverse Event Data

Duration of effects: The clinical studies noted most effects resolved within 72 hours, but adverse event reports suggest some cats may experience prolonged or more severe reactions.

Progression from euphoria/dysphoria to distress: What begins as “euphoria” may progress to more severe agitation in some cats, potentially leading to self-injury or physiological stress.

Temperature regulation issues: The clinical studies documented both hypothermia (94.7% of cats) and hyperthermia (74.3% of cats). The FDA adverse event data suggests these temperature regulation problems may be more serious than initially recognized.

Individual susceptibility: While the original studies excluded cats with various health conditions, real-world usage includes cats with underlying conditions that might make them more vulnerable to severe reactions.

FDA Quarterly Reports

*200 cats on one order

This data comes directly from FDA Animal and Veterinary Event page. Our data collection process is straightforward and transparent. We begin by downloading information in JSON format from the source website. Then, we use a custom Python script to extract specifically the Zorbium®-related data from these files. This extracted data is converted to CSV format, which allows us to perform further analysis in either Microsoft Excel or Google Colab, depending on the analytical needs of our project.